featured
Selpercatinib Yields a 68% ORR and Sustained Durability in Heavily Pretreated RET Fusion - Positive NSCLC
The drug is the first and only RET inhibitor to demonstrate a robust CNS ORR (91%).
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: